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Pathogenic variants in around 100 genes are responsible
for a high risk of early onset solid tumours in close to
1% of the world’s population. As sequencing costs plum-
met and effective drugs are targeted at the molecular
structure of cancers, many more of these gene carriers
will be identified. They are a target population for low
cost prevention strategies in their own right. An added
benefit is that similar molecular pathways are disrupted in
sporadic tumours, so effective chemoprevention strategies
can be extrapolated to the general population. The Cancer
Prevention Programme, CaPP, was developed 25 years ago
to promote genetically targeted cancer prevention trials.
CAPP2, published in 2011 (Burn et al Lancet) was the first
trial with cancer as an endpoint to prove that regular
aspirin significantly reduced the burden of colorectal and
other cancers in people at risk of Lynch syndrome due to
a defective mismatch repair gene. 600mg daily (2 tablets)
for 2 years or more than halved the cancer rate after a lag
of five years. Long term follow up of the other trial which
tested cancer as a cancer preventive, the Women’s Health
Study, has now shown a protective effect of very low dose
aspirin taken on alternate days, but not until 10 years
from the trial start (Cook et al 2013). CaPP3 starts in 2014
and will test the relative benefits of three different blinded
doses of enteric coated aspirin -600mg, 300mg and 100mg
in 3000 gene carriers. Failure of mismatch repair leads to
the generation of frameshift peptides due to unrepaired
slippage in repetitive DNA stretches (microsatellites).
Antibodies to the resulting frame shift peptides will be
tested as possible biomarkers. A vaccine raised against the
important frame shift peptides affecting genes involved in
carcinogenesis is also under investigation.
Our novel nanowire technology is being investigated as
a means of identifying microsatellite instability and BRAF
mutations which help separate sporadic from hereditary
tumours. This will make case identification much cheaper
and easier in the context of countries with a developing
economy.
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